Inspyr Therapeutics, Inc.: Inspyr Therapeutics Further Strengthens Global Intellectual Property
WESTLAKE VILLAGE, CA / ACCESSWIRE / February 18, 2021 / Inspyr Therapeutics, Inc. (OTC PINK:NSPX), a pharmaceutical company focused on the research and development of novel targeted precision therapeutics for the treatment of cancer, announces additional expansion of its global intellectual property portfolio of adenosine receptor antagonists in China, Eurasia, and Israel.
Management continues to execute on the expansion that further provides flexibility to pursue novel treatments based on the specific targets found in multiple types of cancer in different demographics. The issued Eurasia patent and soon to issue Chinese and Israeli patents strengthen the company s global intellectual property portfolio. Per the announcement in December of 2020, 18 patents have already been issued in its intellectual portfolio in potential future commercial markets including the United States, Europe, th
Inspyr Therapeutics Further Strengthens Global Intellectual Property
saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
Inspyr Therapeutics Further Strengthens Global Intellectual Property
pittsburghstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pittsburghstar.com Daily Mail and Mail on Sunday newspapers.
Inspyr Therapeutics Further Strengthens Global Intellectual Property
phoenixherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phoenixherald.com Daily Mail and Mail on Sunday newspapers.
Inspyr Therapeutics, Inc.: Inspyr Therapeutics Secures $500,000 to Support the Development of its Adenosine Pipeline
Funds were secured from an existing institutional investor
WESTLAKE VILLAGE, CA / ACCESSWIRE / January 12, 2021 / Inspyr Therapeutics, Inc. (OTC PINK:NSPX), a pharmaceutical company focused on the research and development of novel targeted precision therapeutics for the treatment of cancer, announces the sale of $500,000 of a senior convertible debenture ( Debenture ) from an existing institutional investor to pursue the research and development of the company s novel portfolio of adenosine receptor antagonists and for general corporate purposes.
The Debenture (i) is non-interest bearing, (ii) has a maturity date of January 12, 2022, (iii) is convertible into shares of common stock at the election of the Investor at any time, subject to beneficial ownership limitations and (iv) has a conversion price equal to the lesser of $0.33 and 85% of the lowest Volume Weighte